1. 19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476). Issue 3 (September 2015) Authors: James, N.D.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Dearnaley, D.P.; Spears, M.R.; Millman, R.; Parker, C.C.; Ritchie, A.W.S.; Russell, J.M.; Staffurth, J.; Jones, R.J.; Cathomas, R.; Robinson, A.; Chowdhury, S.; Tsang, D.; Brock, S.; Parikh, O.; Graham, J.D.; Parmar, M.K.B. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). Issue 3 (September 2015) Authors: Cathomas, R.; Crabb, S.; Kenner, H.; Mark, M.; Rothermundt, C.; Elliott, T.; Winterhalder, R.; Von Burg, P.; Berardi Vilei, S.; Hayoz, S.; Rauch, D.; Roggero, E.; Stenner, F.; Berthold, D.; Erdmann, A.; Fischer, N.; Manetsch, G.; Gillessen, S. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 798PImpact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study. (18th September 2017) Authors: Mark, M.; Klingbiel, D.; Mey, U.; Winterhalder, R.; Rothermundt, C.; Gillessen, S.; von Moos, R.; Manetsch, G.; Cathomas, R. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗